Toxicokinetics of Nerve Agents

Chemical Warfare Agents: Toxicity at Low Levels

Volumn , Issue , 2000, Pages 25-81

  Benschop, Hendrik P ^a   De Jong, Leo P A ^a  

^a TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85152339811     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420041576-5     Document Type: Chapter

References (118)

1. Wolthuis, O.L., Benschop, H.P., and Berends, F., Persistence of the anticholinesterase soman in rats; antagonism with a non-toxic simulator of this organophosphate, Eur. J. Pharmacol., 69, 379, 1981.
2. Kientz, C.E., Langenberg, J.P., and Brinkman, U.A.Th., Micocolumn liquid chromatography with thermionic detection of the enantiomers of O-ethyl S-diisopropylaminoethyl methylphosphonothioate (VX), J. High Resolut. Chromatogr., 17, 95, 1994.
3. Benschop, H.P., Konings, C.A.G., and De Jong, L.P.A., Gas chromatographic separation and identification of the four stereoisomers of 1, 2, 2-trimethylpropyl methylphosphonofluoridate (soman). Stereospecificity of in vitro “detoxification” reactions, J. Am. Chem. Soc., 103, 4260, 1981.
4. Benschop, H.P., Bijleveld, E.C., Otto, M.F., Degenhardt, C.E.A.M., Van Helden, H.P.M., and De Jong, L.P.A., Stabilization and gas chromatographic analysis of the four stereoisomers of 1, 2, 2-trimethylpropyl methylphosphonofluoridate (soman) in rat blood, Anal. Biochem., 151, 242, 1985.
5. Benschop, H.P. and De Jong, L.P.A., Nerve agent stereoisomers: Analysis, isolation and toxicology, Acc. Chem. Res., 21, 368, 1988.
6. Mehlsen-Sørensen, A., (R)-(+)-O-isopropyl-S-(trimethylammonioethyl) methylphosphonothioate iodide, Acta Crystallogr., Sect. B, B33, 1693, 1977.
7. Benschop, H.P., Absolute configuration of chiral organophosphorus anticholinesterases, Pestic. Biochem. Physiol., 5, 348, 1975.
8. De Jong, L.P.A. and Benschop, H.P., Biochemical and toxicological implications of chirality in anticholinesterase organophosphates, in Stereoselectivity of Pesticides. Biological and Chemical Problems, Ariens, E.J., Van Rensen, J.J.S., and Welling, W., eds., Elsevier, Amsterdam, 1988, chap. 4.
9. Ordentlich, A., Barak, D., Kronman, C., Benschop, H.P., De Jong, L.P.A., Ariel, N., Barak, R., Segall, Y., Velan, B., and Shafferman, A., Exploring the active center of human acetylcholinesterase with stereoisomers of an organophosphorus inhibitor with two chiral centers, Biochemistry, 38, 3055, 1999.
10. Benschop, H.P., Konings, C.A.G., Van Genderen, J., and De Jong, L.P.A., Isolation, anticholinesterase properties and acute toxicity in mice of the four stereoisomers of soman, Toxicol. Appl. Pharmacol., 90, 61, 1984.
11. Boter, H.L. and Van Dijk, C., Stereospecificity of hydrolytic enzymes on reaction with asymmetric organophosphorus compounds. III. The inhibition of acetylcholinesterase and butyrylcholinesterase by enantiomeric forms of sarin, Biochem. Pharmacol., 18, 2403, 1969.
12. Hall, C.R., Inch, T.D., Inns, R.H., Muir, A.W., Sellers, D.J., and Smith, A.P., Differences between some biological properties of enantiomers of alkyl S-alkyl methylphosphonothioates, J. Pharm. Pharmacol., 29, 574, 1977.
13. Little, P. J., Reynolds, M. L., Bowman, E. R., and Martin, B. R., Tissue disposition of [3H]sarin and its metabolites in mice, Toxicol. Appl. Pharmacol., 83, 412, 1986.
14. 3H]sarin and their metabolites in mouse brain, Drug Metab. Dispos., 16, 515, 1988.
15. 3H]soman and its pharmacological effects in mice, Toxicol. Appl. Pharmacol., 80, 409, 1985.
16. Harris, L., Broomfield, C., Adams, N., and Stitcher, D., Detoxification of soman and O-cyclopentyl S-diethylaminoethyl methylphosphonothioate in vivo, Proc. West. Pharmacol. Soc., 27, 315, 1984.
17. Göransson-Nyberg, A., Frederiksson, S.-Å., Karlsson, B., Lundström, M., and Cassel, G., Toxicokinetics of soman in cerebrospinal fluid and blood of anaesthetized pigs, Arch. Toxicol., 72, 459, 1998.
18. Benschop, H.P., De Jong, L.P.A., and Langenberg, J.P., Inhalation toxicokinetics of C(±)P(±)-soman and (±)-sarin in the guinea pig, in Enzymes of the Cholinesterase Family, Quinn, D.M., Balasubramanian, A.S., Doctor, B.P., and Taylor, P., eds., Plenum Press, New York, 1995, 361.
19. Benschop, H.P. and De Jong, L.P.A., Toxicokinetics of soman: Species variation and stereospecificity in elimination pathways, Neurosci. Biobehav. Rev., 15, 73, 1991.
20. Benschop, H.P. and De Jong, L.P.A., Toxicokinetic investigations of C(±)P(±)-soman in the rat, guinea pig and marmoset at low doses-Quantification of elimination pathways. Final Report Grant DAMD17-87-7015, NTIS AD-A 226 807, 1990.
21. Maxwell, D.M., Brecht, K.M., and O’Neill, B.L., The effect of CaE’s inhibition on interspecies differences in soman toxicity, Toxicol. Lett., 39, 35, 1987.
22. Due, A.H., Trap, H.C., Van der Wiel, H.J., and Benschop, H.P., The effect of pretreatment with CBDP on the toxicokinetics of soman stereoisomers in rats and guinea pigs, Arch. Toxicol., 67, 706, 1993.
23. Benschop, H.P. and De Jong, L.P.A., Toxicokinetics of the four stereoisomers of soman in the rat., guinea pig and marmoset, Annual/Final Report Grant DAMD17-85-G-5004, NTIS AD-A199 573, 1987.
24. Benschop, H.P. and Van Helden, H.P.M., Toxicokinetics of inhaled soman and sarin in guinea pigs, Final Report Contract DAMD17-90-Z-0034, NTIS AD-A277 585, 1993. See also:
25. Spruit, H.E.T., Langenberg, J.P., Trap, H.C., Van Der Wiel, H.J., Helmich, R.B., Van Helden, H.P.M., and Benschop, H.P., Intravenous and inhalating toxicokinetics of savin stereoisomers in atropinized Guinea pigs, Toxicol. Appl. Pharmacol., in press.
26. Due, A.H., Trap, H.C., Langenberg, J. P., and Benschop, H.P., Toxicokinetics of soman stereoisomers after subcutaneous administration to atropinized guinea pigs, Arch. Toxicol., 68, 60, 1994.
27. Oberst, F.W., Factors affecting inhalation and retention of toxic vapors, in Inhaled Particles and Vapours, Davies, C. N., ed., Pergamon Press, Oxford, 1961, 249.
28. Oberst, F.W., Koon, W.S., Christensen, M.K., Crook, J.W., Cresthull, B.S., and Freeman, G., Retention of inhaled sarin vapor and its effect on red blood cell cholinesterase activity in man, Clin. Pharmacol. Ther., 9, 421, 1968.
29. Langenberg, J.P., Spruit, H.E.T., Van Der Wiel, H.J., Trap, H.C., Helmich, R.B., Bergers, W.W.A., Van Helden, H.P.M., and Benschop, H.P., Inhalation toxicokinetics of soman stereoisomers in the atropinized guinea pig with nose-only exposure to soman vapor, Toxicol. Appl. Pharmacol., 151, 79, 1998.
30. Ainsworth, M. and Shepherd, R.J., The intrabronchial distribution of soluble vapors at selected rates of gas flow, in Inhaled Particles and Vapours, C.N. Davies, ed., Pergamon Press, Oxford, 1961, 233.
31. Reed, C.J., Drug metabolism in the nasal cavity: Relevance to toxicology, Drug Metab. Rev., 25, 173, 1993.
32. Dahl, A.R. and Gerde, P., Uptake and metabolism of toxicants in the respiratory tract. Environm. Health Perspect., 102, 67, 1994;
33. see also Miller, F.J. and Kimball, J.S., Regional dosimetry of inhaled reactive gases, in Concepts in Inhalation Toxicology, McClellan, R.O. and Henderson, R.F., eds., Taylor and Francis, Washington, 1995, 257.
34. Ember, L., Probe of troops’ exposure to chemical arms failed, Chem. Eng. News, Sept. 23, 40, 1996.
35. Central Intelligence Agency, Modeling the Chemical Warfare Agent Release at the Khamisiyah Pit, 1997, www.gulflink.osd.mil/cia_092297
36. Croddy, E., Urban terrorism-chemical warfare in Japan,. Jane’s Intelligence Rev., November 1995, 520.
37. Nozaki, H., Hori, S., Shinozawa, S., Fujishima, S., Takuma, K., Sagoh, M., Kimura, H., Ohki, T., Suzuki, M., and Aikawa, N., Secondary exposure of medical staff to sarin vapor in the emergency room, Intensive Care Med., 21, 1032, 1995.
38. Brackett, D.W., Armageddon in Tokyo, Weatherhill, New York, 1996.
39. Okudera, H., Morita, H., Iwashita, H., Shibata, T., Otagiri, T., Kobayashi, S., and Yanagisawa, N., Unexpected nerve gas exposure in the city of Matsumoto: Report of rescue activity in the first sarin gas terrorism, Am. J. Emerg. Med., 15, 527, 1997.
40. Suzuki, J., Kohno, T., Tsukagosi, M., Furuhata, T., and Yamazaki, K., Eighteen cases exposed to sarin in Matsumoto, Japan, Intern. Med., 36, 466, 1997.
41. Nakajima, T., Sato, S., Morita, H., and Yanagisawa, N., Sarin poisoning of a rescue team in the Matsumoto incident in Japan, Occup. Environ. Med., 54, 697, 1997.
42. National Research Council (Committee on Toxicology), Possible Long-Term Effects of Short Term Exposure to Chemical Agents. Vol. 3. Final Report. Current health status of test subjects. NTIS AD-A163 614, 1985.
43. Okumura, T., Takasu, N., Ishimatsu, S., Miyanoka, S., Mitsuhashi, A., Kumada, K., and Hinohara, S., Report on 640 victims of the Tokyo subway attack, Ann. Emerg. Med., 28, 129, 1996.
44. Murata, K., Araki, S., Yokoyama, K., Okumura, T., Ishimatsu, S., Takasu, N. and White, R.F., Asymptomatic sequelae to acute sarin poisoning in the central and autonomic nervous system 6 months after the Tokyo subway attack, J. Neurol., 244, 601, 1997.
45. Yokoyama, K., Araki, S., Murata, K., Nishikitani, M., Okumura, T., Ishimatsu, S., Takasu, N., and White, R. F., Chronic neurobehavioral effects of Tokyo subway sarin poisoning in relation to posttraumatic stress disorder, Arch. Environ. Health, 53, 249, 1998.
46. Nakajima, T., Ohta, S., Fukushima, Y., and Yanagisawa, N., Sequelae of sarin toxicity at one and three years after exposure in Matsumoto, Japan, J. Epidemiol., 9, 337, 1999.
47. Benschop, H.P., Trap, H.C., Spruit, E.T., Van Der Wiel, H.J., Langenberg, J.P., and De Jong, L.P.A., Low level-nose only exposure to the nerve agent soman: toxicokinetics of soman stereoisomers and cholinesterase inhibition in atropinized guinea pigs, Toxicol. Appl. Pharmacol., 153, 179, 1998.
48. Jacobson, K.H., Christensen, M.K., DeArmon, I.A., and Oberst, F.W., Studies of chronic exposures of dogs to GB (isopropyl methylphosphonofluoridate) vapor, Arch. Ind. Health, 19, 5, 1959.
49. Moylan-Jones, R.J. and Price Thomas, D., Cyclopentolate in treatment of sarin miosis, Br. J. Pharmacol., 48, 309, 1973.
50. Ballantyne, B. and Marrs, T.C., Organophosphates and Carbamates, Butterworth Heinemann, Oxford, 1992, 380.
51. Rubin, L.S. and Goldberg, M.N., Effect of sarin on dark adaptation in man: threshold changes, J. Appl. Physiol., 11, 439, 1957.
52. Mioduszewski, R.J., Reutter, S.A., Miller, L.L., Olajos, E.J., and Thomson, S.A., Evaluation of airborne exposure limits for G-agents: occupational and general population exposure criteria, Report ERDEC-TR-489, Edgewood Research, Development and Engineering Center, April 1998. See also: Fact sheet on exposure limits for sarin (GB), July 1997, http://www.gulflink.osd.mil/dugway/low_lv_chem_fact.htm.
53. Polhuijs, M., Langenberg, J.P., and Benschop, H.P., New method for retrospective detection of exposure to organophosphate anticholinesterases: Application to alleged sarin victims of Japanese terrorists, Toxicol. Appl. Pharmacol., 146, 156, 1997.
54. Van Helden, H.P.M., Langenberg, J.P., and Benschop, H.P., Low level exposure to GB vapor in air: diagnosis/dosimetry, lowest observable effect levels, performance-incapacitation and possible delayed effects, Contract DAMD17-97-1-7360, U.S. Army Medical Research and Materiel Command. See also: Trap, H.C., Kuijpers, W.C., Groen, B., Oostdijk, J.P., Vanwersch, R.A.P., Philippens, H.C., Langenberg, J.P., Benschop, H.P., and Van Helden, H.P.M., Low-level exposure to GB in air: diagnosis/dosimetry, lowest observable effect level (LOEL), and lowest observable adverse effect level (LOAEL), Grant DAMD17-97-1-7360, U.S. Army Medical Command.
55. Mazur, A., An enzyme in animal tissues capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphates, J. Biol. Chem., 164, 271, 1946.
56. Mounter, L.A., Metabolism of organophosphorus anticholinesterase agents, in Handbuch der Experimentellen Pharmakologie. Vol. XV. Cholinesterases and Anticholinesterase Agents, Koelle, G.B., ed., Springer, Berlin, 1963, chap. 10.
57. Adie, P.A. and Tuba, J., The intracellular localization of liver and kidney sarinase, Can. J. Biochem. Biophys., 36, 21, 1958.
58. Adie, P.A., Hoskin, F.C.G., and Trick, G.S., Kinetics of the enzymatic hydrolysis of sarin, Can. J. Biochem. Biophys., 64, 80, 1958.
59. Augustinsson, K.-B. and Heimburger, G., The enzymic hydrolysis of organophosphorus compounds. I. Occurrence of enzymes hydrolyzing tabun, Acta Chem. Scand., 8, 753, 1954.
60. Cohen, J.A. and Warringa, M.P.G.J., Purification and properties of dialkylfluorophosphatase, Biochim. Biophys. Acta, 26, 29, 1957.
61. Millard, C.B., Lockridge, O., and Broomfield, C.A., Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase, Biochemistry, 34, 15925, 1995.
62. Lockridge, O., Blong, R.M., Masson, P., Froment, M.T., Millard, C.B., and Broomfield, C.A., A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase, Biochemistry, 36, 786, 1997.
63. Noort, D., Hulst, A.G., Platenburg, D.H.J.M., Polhuijs, M., and Benschop, H.P., Quantitative analysis of O-isopropyl methylphosphonic acid in serum samples of Japanese citizens allegedly exposed to sarin: Estimation of internal dose, Arch. Toxicol., 72, 671, 1998.
64. Minami, M., Hui, D.-M., Katsumata, M., Inagaki, H., and Boulet, C., Method for the analysis of methylphosphonic acid metabolites of sarin and its ethanol-substituted analogue in urine as applied to the victims of the Tokyo sarin disaster, J. Chromatogr. B., 695, 237, 1997.
65. Harris, L.W., Braswell, L.M., Fleisher, J.H., and Cliff, W.J., Metabolites of pinacolyl methylphosphonofluoridate (soman) after enzymatic hydrolysis in vitro, Biochem. Pharmacol., 13, 1129, 1964.
66. 32P) from the mouse circulatory system, Biochem. Pharmacol., 16, 2061, 1967.
67. Nakajima, T., Sasaki, K., Sekjima, Y., Morita, H., Fukushima, Y., and Yanagisawa, N., Urinary metabolites of sarin in a patient of the Matsumoto sarin incident, Arch. Toxicol., 72, 601, 1998.
68. Christen, P.J. and Van den Muysenberg, J.A.C.M., The enzymatic isolation and fluoride catalysed racemisation of optically active sarin, Biochim. Biophys. Acta, 110, 217, 1965.
69. Christen, P.J., Berends, F., and Cohen, E.M., The influence of stereoisomerism of sarin on various reactions with sarinase and cholinesterase, Acta Physiol. Pharmacol. Neerl., 14, 338, 1967.
70. De Bisschop, H.C., Mainil, J.G., and Willems, J.L., In vitro degradation of the four stereoisomers of soman in human serum, Biochem. Pharmacol., 34, 1895, 1985.
71. De Bisschop, H.C., De Meerleer, W.A.P., Van Hecke, P.R.J., and Willems, J.L., Stereoselective hydrolysis of soman in human plasma and serum, Biochem. Pharmacol., 36, 3579, 1987.
72. De Bisschop, H.C., De Meerleer, W.A.P., and Willems, J.L., Stereoselective phosphonylation of human serum proteins by soman, Biochem. Pharmacol., 36, 3587, 1987.
73. De Jong, L.P.A., Van Dijk, C., and Benschop, H.P., Hydrolysis of the four stereoisomers of soman catalyzed by liver homogenate and plasma from rat, guinea pig and marmoset and by human plasma, Biochem. Pharmacol., 37, 2939, 1988.
74. De Jong, L.P.A., Van Dijk, C., Berhitoe, D., and Benschop, H.P., Hydrolysis and binding of a toxic stereoisomer of soman in plasma and tissue homogenates from rat, guinea pig and marmoset, and in human plasma, Biochem. Pharmacol., 46, 1413, 1993.
75. Langenberg, J.P., Van Dijk, C., Sweeney, R.E., Maxwell, D.M., De Jong, L.P.A., and Benschop, H.P., Development of a physiologically based model for the toxicokinetics of C(±)P(±)-soman in the atropinized guinea pig, Arch. Toxicol., 71, 320, 1997.
76. Augustinsson, K.-B., Enzymatic hydrolysis of organophosphorus compounds. VII. The stereospecificity of phosphoryl phosphatases, Acta Chem. Scand., 11, 1371, 1957.
77. Degenhardt, C.E.A.M., Van den Berg, G.R., De Jong, L.P.A., Benschop, H.P., Van Genderen, J., and Van de Meent, D., Enantiospecific complexation gas chromatography of nerve agents. Isolation and properties of the stereoisomers of ethyl N, N-dimethylphosphoramido-cyanidate (tabun), J. Am. Chem. Soc., 108, 8290, 1986.
78. Myers, D.K., Cholinesterase. VII. Determination of the molar concentration of pseudocholinesterase in serum, Biochem. J., 51, 303, 1952.
79. 32P, Biochem. Pharmacol., 18, 813, 1969.
80. Sterri, S.H. and Fonnum, F., Detoxification of organophosphorus compounds, in Cholinesterases. Fundamental and Applied Aspects, Brzin, M., Barnard, E.A., and Sket, D., eds., de Gruyter, Berlin, 1984, 110.
81. 32P-sarin to esterases and other proteins in plasma from rat, man and guinea-pig, Acta Physiol. Pharmacol. Neerl., 15, 36, 1969.
82. Black, R.M., Harrison, J.M., and Read, R.W., The interaction of sarin and soman with plasma proteins: the identification of a novel phosphylation site, Arch. Toxicol., 73, 123, 1999.
83. Maxwell, D.M., Lenz, D.E., Groff, W.A., Kaminskis, A., and Froehlich, H.L., The effects of blood flow and detoxification on in vivo cholinesterase inhibition by soman in rats, Toxicol. Appl. Pharmacol., 88, 66, 1987.
84. Myers, D.K., Mechanism of the prophylactic action of diacetylmonoxime against sarin poisoning, Biochim. Biophys. Acta, 34, 555, 1959.
85. McKay, D.H., Jardine, R.V., and Adie, P.A., The synergistic action of 2-(o-cresyl)-4H-1:3:2- benzodioxaphosphorin-2-oxide with soman and physostigmine, Toxicol. Appl. Pharmacol., 20, 474, 1971.
86. Sterri, S.H. and Fonnum, F., CaE’s-the soman scavenger in rodents; heterogeneity and hormonal influence, in Enzymes Hydrolysing Organophosphorus Compounds, Reiner, E., Aldridge, W.N., and Hoskin, F.C.G., eds., Ellis Horwood Ltd., Chichester, 1989, chap. 14.
87. Sterri, S.H., Lyngaas, S., and Fonnum, F., Toxicity of soman after repetitive injection of sublethal doses in rats, Acta Pharmacol. Toxicol., 46, 1, 1980.
88. Sterri, S.H., Lyngaas, S., and Fonnum, F., Toxicity of soman after repetitive injection of sublethal doses in guinea-pig and mouse, Acta Pharmacol. Toxicol., 49, 8, 1981.
89. Doctor, B.P., Blick, D.W., Caranto, G., Castro, C.A., Gentry, M.K., Larrison, R., Maxwell, D.M., Murphy, M.R., Schutz, M., Waibel, K., and Wolfe, A.D., Cholinesterases as scavengers for organophosphorus compounds: Protection of primate performance against soman toxicity, Chem.-Biol. Interact., 87, 285, 1993.
90. Maxwell, D.M., Castro, C.A., De La Hoz, D.M., Gentry, M.K., Gold, M.B., Solana, R.P., Wolfe, A.D., and Doctor, B.P., Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase, Toxicol. Appl. Pharmacol., 115, 44, 1992.
91. Raveh, L., Grauer, E., Grunwald, J., Cohen, E., and Ashani, Y., The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase, Toxicol. Appl. Pharmacol., 145, 43, 1997.
92. Allon, N., Raveh, L., Gilat, E., Cohen, E., Grunwald, J., and Ashani, Y., Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase, Toxicol. Sci., 43, 121, 1998.
93. 32P mouse organs. I. The effect of route of administration on incorporation and toxicity, Biochem. Pharmacol., 15, 169, 1966.
94. 14C-soman in rats, The Pharmacologist, 25, 111, 1983.
95. Heilbronn, E., Appelgren, I.-E., and Sundwall, A., The fate of tabun in atropine and atropine oxime treated rats and mice, Biochem. Pharmacol., 13, 1189, 1964.
96. Hansen, D., Schaum, E., and Wasserman, O., Distribution and metabolism of diisopropyl phosphorofluoridate (DFP) in the guinea pig, Arch. Toxicol., 23, 73, 1968.
97. Hansen, D., Schaum, E., and Wasserman, O., Serum level and excretion of diisopropyl fluorophosphate (DFP) in cats, Biochem. Pharmacol., 17, 1159, 1968.
98. De Jong, L.P.A., Benschop, H.P., Due, A., Van Dijk, C., Trap, H.C., Van der Wiel, H.J., and Van Helden, H.P.M., Soman levels in kidney and urine following administration to rat, guinea pig, and marmoset, Life Sci., 50, 1057, 1992.
99. De Jong, L.P.A. and Van Dijk, C., Formation of soman (1, 2, 2-trimethylpropyl methylphosphonofluoridate) via fluoride-induced reactivation of soman-inhibited aliesterase in rat plasma, Biochem. Pharmacol., 33, 663, 1984.
100. Dedrick, R.L., Forrester, D.D., Cannon, J.N., El Dareer, S.M., and Mellett, L.B., Pharmacokinetics of 1-β-D-arabinofuranosylcytosine (ARA-C) deamination in several species, Biochem. Pharmacol., 22, 2405, 1973.
101. King, F.G., Dedrick, R.L., Collins, J.M., Matthews, H.B., and Birnbaum, L.S., Physiological model of the pharmacokinetics of 2, 3, 7, 8-tetrachlorodibenzofuran in several species, Toxicol. Appl. Pharmacol., 67, 390, 1983.
102. Lutz, R.J., Dedrick, R.L., Tuey, D., Sipes, I.G., Anderson, M.W., and Matthews, H.B., Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model, Drug Metab. Dispos., 12, 527, 1984.
103. Ramsey, J.C. and Andersen, M.E., A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans, Toxicol. Appl. Pharmacol., 73, 159, 1984.
104. Maxwell, D.M., Vlahacos, C.P., and Lenz, D.E., A pharmacodynamic model for soman in the rat, Toxicol. Lett., 43, 175, 1988.
105. Gearhart, J.M., Jepson, G.W., Clewell III, H.J., Andersen, M.E., and Conolly, R.B., Physiologically based pharmacokinetics and the pharmacodynamic model for inhibition of acetylcholinesterase by diisopropyl fluorophosphate, Toxicol. Appl. Pharmacol., 106, 295, 1990.
106. McPhail, M.K. and Adie, P.A., The distribution of radioactive phosphorus in the blood and tissues of rabbits treated with tagged sarin, Can. J. Biochem. Physiol., 38, 945, 1960.
107. De Jong, L.P.A., Langenberg, J.P., and Benschop, H.P., TNO Prins Maurits Laboratory, unpublished data, 1999.
108. Rakusan, K. and Blahitka, J., Cardiac output distribution in rats measured by injection of radioactive microspheres via cardiac puncture, Can. J. Physiol. Pharmacol., 52, 230, 1974.
109. Ashani, Y., Grunwald, J., Raveh, L., Grauer, E., Brandeis, R., Marcus, D., Papier, Y., Kadar, T., Allon, N., Gilat, E., and Lerer, S., Cholinesterase prophylaxis against organophosphorus poisoning, Final Report Contract DAMD17-90-C-0033, NTIS ADA277 096, 1993.
110. Keijer, J.H. and Wolring, G.Z., Stereospecific aging of phosphonylated cholinesterases, Biochim. Biophys. Acta, 185, 465, 1969.
111. Vojvodic, V. and Milosevic, M., Some pharmacological actions of oximes and atropine on the cadiovascular effects produced by pinacolyl methylphosphonofluoridate (soman) in rats, Iugosl. Physiol. Pharmacol. Acta, 7, 439, 1971.
112. Kentera, D., Susic, D., and Stamenovic, B., The effects of HS-3 and HS-6 on cardiovascular changes in rats caused by soman, Arh. Hig. Rada Toksikol., 33, 143, 1982.
113. Langenberg, J.P., De Jong, L.P.A., and Benschop, H.P., Kinetic modeling of pretreatment against soman poisoning, in Book of Abstracts 1991 EUROTOX Congress, Maastricht, 1991, 244.
114. Bajgar, J., Fusek, J., Patocka, J., and Hrdina, V., Detoxication of phosphonothioates and phosphonofluoridates in the rat, Acta Biol. Med. Germ., 37, 1261, 1978.
115. Wang, Q., Sun, M., Zhang, H., and Huang, C., Purification and properties of somanhydrolyzing enzyme from human liver, J. Biochem. Mol. Toxicol., 12, 213, 1998.
116. Maxwell, D.M., The specificity of carboxylesterase protection against the toxicity of organophosphorus compounds, Toxicol. Appl. Pharmacol., 114, 306, 1992.
117. Rocha, E.S., Santos, M.D., Chebabo, S.R., Aracava, Y., and Albuquerque, E.X., Low concentrations of the organophosphate VX affect spontaneous and evoked transmitter release from hippocampal neurons: Toxicological relevance of cholinesterase-independent actions, Toxicol. Appl. Pharmacol., 159, 31, 1999.
118. Van der Schans, M.J., Langenberg, J.P., and Benschop, H.P., Toxicokinetics of O-ethyl S-(2-diisopropylaminoethyl) methylphosphonothioate [(±)-VX] in hairless guinea pigs and marmosets-Identification of metabolic pathways, Final Report Contract DAMD17-97-2-7001, 2000.